lumocaserin   Click here for help

GtoPdb Ligand ID: 14747

Synonyms: compound (+)-16a [PMID: 25633969]
Compound class: Synthetic organic
Comment: Lumocaserin is the INN for a serotonin 5-HT2C receptor agonist, with anti-epileptic potential. The structure provided in the INN record is identical to that for compound (+)-16a in [2], and additional 2-phenylcyclopropylmethylamine-based 5-HT2C agonists similar to lumocaserin are described in [3]. Analysis of available patent and peer-reviewed information around compounds with this core structural scaffold strongly suggests that lumocaserin is the INN for Bright Minds Biosciences' clinical candidate BMB-101, which is in development as an anti-epileptic agent. BMB-101 exhibits bias for Gq-mediated signaling. It does not induce β-arrestin recruitment and therefore does not cause 5-HT2C receptor desensitization.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 35.25
Molecular weight 223.29
XLogP 1.44
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCOC1=CC=C(C=C1[C@H]2C[C@@H]2CN)F
Isomeric SMILES CCCOC1=C(C=C(C=C1)F)[C@H]2C[C@@H]2CN
InChI InChI=1S/C13H18FNO/c1-2-5-16-13-4-3-10(14)7-12(13)11-6-9(11)8-15/h3-4,7,9,11H,2,5-6,8,15H2,1H3/t9-,11+/m1/s1
InChI Key PHNQBSADACIRLN-KOLCDFICSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Bialer M, Johannessen Landmark C, Koepp MJ, Perucca E, Perucca P, Tomson T, White HS, Wirrell E. (2026)
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Epilepsia, 67 (10): 5075-5125. [PMID:42470359]
2. Cheng J, Giguère PM, Onajole OK, Lv W, Gaisin A, Gunosewoyo H, Schmerberg CM, Pogorelov VM, Rodriguiz RM, Vistoli G et al.. (2015)
Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
J Med Chem, 58 (4): 1992-2002. [PMID:25633969]
3. Cheng J, Kozikowski AP. (2015)
We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.
ChemMedChem, 10 (12): 1963-7. [PMID:26507582]